Gregory Stock is a biophysicist, best-selling author, biotech entrepreneur, and the former director of the Program on Medicine, Technology and Society at UCLA’s School of Medicine. His interests lie in the scientific and evolutionary as well as ethical, social and political implications of today's revolutions in the life sciences and in information technology and computers.
Arthur D. Levinson is an American businessman and is the current Chairman of Apple Inc. and CEO of Calico. He is the former chief executive officer and chairman of Genentech.
Sheridan Gray Snyder OBE is an entrepreneur, venture capitalist, and philanthropist. in the biotechnology industry. He is the founder and CEO of Biocatalyst, but also a "serial entrepreneur", a founder of Genzyme and many other companies. Snyder, who was the University of Virginia's best tennis player when he was studying for his BA in French and Romance Languages there in the 1960s, made "major contributions to the popularisation of tennis in the USA." He co-founded the National Junior Tennis League that reaches 250,000 inner-city young people and constructed a new tennis center at the University of Virginia.
FlandersBio, founded in 2004, is the networking organisation for the life sciences sector in Flanders and represents and supports close to 300 member companies. The key strategic objectives of FlandersBio are knowledge exchange and valorisation, human capital development, internationalization of the cluster activities and visibility, familiarization of the public with products derived from the sector and the further development of a supportive environment for the members of FlandersBio.
Fakir Mohan University is named after prominent Odia writer Fakir Mohan Senapati. The seat of the Vice-Chancellor is in the new campus located at Nuapadhi, Balasore, Odisha, India.
UF Innovate | Sid Martin Biotech is located in Alachua, Florida, in Progress Park. The program's mission is to foster the growth of bioscience startup companies that have some relationship to the University. The Incubator works with companies in all product areas relating to the life sciences, biomedical research, medicine, and chemical sciences.
Network for Excellence in Health Innovation (NEHI), formerly New England Healthcare Institute is a member-based, non-partisan research and policy organization.
Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio describes its platform as single molecule real time sequencing (SMRT), based on the properties of zero-mode waveguides. The company's first commercial product, the PacBio RS, was sold to a limited set of customers in 2010 and was commercially released in early 2011. A subsequent version of the sequencer called the PacBio RS II was released in April 2013. On September 25, 2013 a partnership between Pacific Biosciences and Roche Diagnostics was announced for the development of in vitro diagnostic products using the technology, with Roche providing US$75,000,000 in the deal. In 2015, the company launched a new sequencing instrument called the Sequel System with approximately 7-fold greater capacity than the PacBio RS II. Then in April 2019 the company launched the Sequel II system with a further 8-fold increase in throughput.
Earlham Institute is a life science research institute located at the Norwich Research Park (NRP), Norwich, England. EI's research is focused on exploring living systems by applying computational science and biotechnology to answer ambitious biological questions and generate enabling resources.
Life Sciences Foundation (LSF) was a San Francisco-based nonprofit organization that was established in 2011 to collect, preserve, interpret, and promote the history of biotechnology. LSF conducted historical research, maintained archives and published historically relevant materials and information.
Thomas Baer is the Executive Director of the Stanford Photonics Research Center, a consulting professor in the Applied Physics Department and an Associate Member of the Stem Cell Institute at Stanford University. His current scientific research is focused on developing imaging and biochemical analysis technology for exploring the molecular basis of human developmental biology and neuroscience. He received a B.A. in physics from Lawrence University in 1974, and a Ph.D. in atomic physics from the University of Chicago in 1979, where he studied with Professors Ugo Fano and Isaac Abella. After receiving his Ph.D. he worked with Nobel Laureate John L. Hall at JILA, University of Colorado, performing research on frequency stabilized lasers and ultra-high precision molecular spectroscopy.
The VA Bio+Tech Park is a 34-acre commercial life sciences hub in downtown Richmond, Virginia adjacent to the VCU Medical Center at Virginia Commonwealth University. The park was incorporated in 1992 and opened in 1995. It houses nearly 70 public and private life sciences companies, research institutes affiliated with VCU, and prominent state and national medical laboratories. Residents include the national headquarters for the United Network for Organ Sharing (UNOS), the Virginia Department of Forensic Science, the Virginia Office of the Chief Medical Examiner, and True Health Diagnostics. The park's largest tenant is Richmond-based Altria Group, Inc., which opened the metal-clad, 450,000-square-foot, $350 million Center for Research & Technology on the site in 2007. The heavily secured complex employs 600 scientists, engineers and support staff.
NCBioImpact is a partnership of North Carolina organizations created to enhance the trained workforce for biotechnology and other life science employers by educating students and retraining incumbent workers. The partnership works to promote economic development in North Carolina while offering comprehensive biomanufacturing training and education programs located at two universities in the University of North Carolina System and the North Carolina Community College System.
Jeff Aronin is an American investor, entrepreneur, and biopharmaceutical executive. He is chairman and CEO of Paragon Biosciences, LLC, an innovation-based life sciences company that develops, accelerates and finances new companies that create major biotechnology advancements to improve patient care. Paragon Biosciences’ companies focus on patients suffering from debilitating diseases with no effective treatment. The Paragon Biosciences team has succeeded in getting 13 Novel Drug Approvals through the FDA. Aronin is also chairman, CEO and founder of Paragon Pharmaceutical Capital, LLC, an investment firm that backs healthcare companies.
Sara Radcliffe is an American medical research advocate and business executive. She is the president and CEO of California Life Sciences Association, a non-profit organization that advocates for the medical research mission of the life sciences sector of California. She is best known for her expertise in the field of applied public health and an advocate for life sciences.
Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, alumni. Termeer is "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.
The Biotechnology Innovation Organization (BIO) is the largest trade organization in the world that represents the biotechnology industry. It was founded in 1993 as the Biotechnology Industry Organization, and changed its name to the Biotechnology Innovation Organization on January 4, 2016. Biotechnology Innovation Organization serves more than 1,100 biotechnology firms, research schools, state biotechnology centers and related associations in the United States and in more than 30 other countries.
The Indiana Biosciences Research Institute (IBRI) is an American nonprofit research and technology organization serving the state of Indiana. The IBRI is the nation's first industry-led collaborative life sciences research institute. Their work focuses on targeting diabetes, metabolic disease, and poor nutrition.
David L. Lucchino is a life sciences CEO and American entrepreneur known for his work in the biotechnology and medical technology sectors. Currently he is co-founder, president and CEO of Frequency Therapeutics (Nasdaq:FREQ), a clinical-stage biotechnology company developing a novel approach to regenerative medicine to create and commercialize therapeutics for degenerative conditions including hearing loss and multiple sclerosis. as well as treatments for other conditions, based on a unique approach to regenerative medicine.
William H. Rastetter, a scientist, entrepreneur and venture capitalist, is the chair of Neurocrine Biosciences, of Fate Therapeutics, and of Daré Bioscience, Inc. in San Diego, California. He is a founding board member and investor in GRAIL, Inc. in Menlo Park, California, and served for a period as the company’s interim CEO (2017) and chair (2017-2018).. Rastetter is also a director of Regulus Therapeutics. He was a partner in the venture firm Venrock (2006-2013), and a trustee at Caltech (2015-2018). He has served as a director (1998-2016) and as chair of Illumina (2005-2016). He advises SVB Leerink and Illumina Ventures.
